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Oral Presentations 7dose is critical for UCBT. Previously mortality risks outweigh ben-
efits in using UCBT for thalassemia.With strategies that maximize
cell dose – using non-red cell reduced but plasma depleted (PD)CB,
no post-thawwash (NW), and double cord transplantation (DCT) –
promising results may be achieved with UCBT in young thalasse-
mics. Between 7/2001 and 1/2006, 63 CB products were infused af-
ter Bu/Cy/ATG myeloablation in 51 pediatric thalassemia major
patients (11 DCT & 1 re-transplant) at 14 transplant centers
(TC) using 82% PD CB with 92% NW. Patient status: 20 Pesaro
class 1, 11 class 2, 1 class 3, and 19 status unknown. Median age
was 4.3 years (range 0.3–20 years) with a median weight of 17 kg
(range 4–45 kg). The data was audited by TC, NMDP and on-
site by CIBMTR with 97.3% accuracy. No significant adverse
events were observed despite major ABO incompatibility in some
cases and NW. Cumulative incidence estimates of neutrophil
(ANC500), platelet 20K and platelet 50K (plt 20 & 50K) engraft-
ment with donor chimerism were 86 6 8%, 74 6 9% and 74 6
9%, and median times to ANC500, plt 20K and 50K engraftment
were 17 days (range 11–32), 40 days (range 16–135) and 60 days
(range 30–144) after transplantation respectively. 7 patients died in-
cluding 2 deaths prior to day 20 and one due to traumatic head in-
jury. 42 patients engrafted, 9 with autologous recovery, and 38
patients are alive with a mean and median follow up time of 537
and 296 days respectively (range 8–2,691 days) as of May 2007. Re-
sults appear to show improvement with TC experience TC (.5
cases of UCBT for thalassemia) and NW. Patients receiving PD
versus red cell depletion (RCD) CB were compared by matched-
pair analyses where patients were matched by TC experience,
wash status, age, weight, TNC dose, and #HLA matches (Paired
Prentice-Wilcoxon Test). The results (table) showed fewer autolo-
gous recovery (p5 0.04) and better thalassemia-free survival (DFS;
p5 0.01) for PD compared to RCD patients. Overall survival (OS)
and transplant-related mortality (TRM) also trended in favor of PD
patients (both p5 0.08). To our knowledge, this is the largestmulti-
institutional UCBT series for thalassemia and demonstrate that at
experienced TC, 93 6 6% ANC engraftment and 88 6 8% 1-
year DFS are attainable, when cell dose is optimized with PD
CBU, no post-thaw wash and DBT when necessary.
Autologous
ANC500 Plt 50 K Recovery TRM OS DFSP-value NS NS 0.04 0.08 0.08 0.01
In favor of PD PD PD PDNS 5 Not Significant.
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THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION
(AlloSCT) FOR THE TREATMENT OF THERAPY-RELATED MYELODYS-
PLASTIC SYNDROME (tMDS) AND ACUTE MYELOID LEUKEMIA (tAML)
VARIES CONSIDERABLY BY RISK FACTOR: AN OBSERVATIONAL STUDY
FROM THE CENTER FOR INTERNATIONAL BLOOD AND MARROW
TRANSPLANT RESEARCH (CIBMTR)
Litzow, M.R.1, Perez, W.S.2, Tarima, S.2, Keating, A.3, Sierra, J.4,
Tallman, M.S.5, Weisdorf, D.J.6. 1Mayo Clinic Rochester; 2Center for
International Blood and Marrow Transplant Research; 3Princess Mar-
garet Hospital for Children; 4Hospital de la Santa Creu i Sant Pau;
5Northwestern Memorial Hospital; 6University of Minnesota Medical
Center.
We report outcomes of alloSCT for tMDS and tAML in 868 sub-
jects transplanted between 1990 and 2004 at 211 centers in 33 coun-
tries. 21% were#19 years old (yo); 55% were female and 63% had
tAML (including 30% with prior tMDS). Prior treatment was che-
motherapy in 43%, chemotherapy and radiation therapy in 51%
and radiation therapy alone in 4%. Prior diagnoses included Hodg-
kin lymphoma (23%) and non-Hodgkin lymphoma (21%), breast
cancer (16%), ALL (12%), sarcoma (8%), germ cell tumor (6%),
and autoimmune disorders (5%). Cytogenetic data (cd) at the
time of transplant were known in 84%: good prognosis 4%, inter-
mediate 61% and poor 34%. The IPSS score at diagnosis for sub-jects with tMDS was intermediate-2 or high in 54%. At
transplant, 51% of subjects with tAMLwere in first complete remis-
sion (CR1), 7% $ CR2, 15% in relapse and 27% were primary in-
duction failures. For the tMDS pts, 37% had been treated with
other modalities before receiving an alloSCT. Pre-transplant con-
ditioning regimen was myeloablative (M) 77% and reduced inten-
sity (RI or non-M) in the remainder. Donors were related 38%
and unrelated 62%; 66% of the grafts were bone marrow and
34% peripheral blood stem cells. Cumulative incidence of acute
GVHD (grade II-IV) @100 days was 39% (95% confidence interval
[CI]), 35–42). Outcomes, with a median follow-up of 61 (range, 3–
187) months were: In multivariate analysis (MVA), DFS and OS
were lower in subjects .35 yo, with poor prognosis cd, AML not
in CR or untreatedMDS, or with amismatched related or unrelated
donor. The use of a RI or non-M conditioning regimen did not im-
prove outcomes in the MVA. Survival was significantly better in pts
\35 yo, with good or intermediate risk cd, disease control at the
time of transplant and having a matched related or complete or par-
tially matched-unrelated donor. The 5 year survival was 50% (95%
CI, 39–61) with all 4 good risk factors (grf); 25% (95% CI, 20–31)
with any 3 grf, 19% (95% CI, 14–24) with any 2 grf, 12% (95% CI,
8–18) with only 1 grf, and only 4% (95% CI, 0–15) without any of
these factors. In conclusion, easily identifiable risk factors predict
outcome after alloSCT for tMDS and tAML.
5 year probability
Outcome: (95% CI)Chronic GVHD 30 (27–33)
Treatment-related mortality (TRM) 48 (44–51)
Relapse 31 (28–34)
Disease-free survival (DFS) 21 (18–24)
Overall survival (OS) 22 (19–26)14
UNRELATED CORD BLOOD TRANSPLANTATION AFTERMYELOABLATIVE
CONDITIONING IN 98 ADULT PATIENTSWITH ACUTE LEUKEMIA: A SIN-
GLE-INSTITUTE EXPERIENCE IN JAPAN
Ooi, J., Takahashi, S., Tomonari, A., Tsukada, N., Konuma, T.,
Kato, S., Kasahara, S., Tojo, A., Asano, S. Institute of Medical Science,
University of Tokyo, Tokyo, Japan.
We analyzed outcomes and risk factors after unrelated cord blood
transplantation (CBT) for 98 adult patients with acute leukemia.
Between August 1998 and June 2007, 98 adult patients with acute
leukemia were treated with unrelated CBT at The Institute ofMed-
ical Science, University of Tokyo. Diagnoses at transplantation in-
cluded de novo AML (n 5 55), ALL (n 5 25), and MDS-related
secondary AML (n 5 18). 59 (60%) patients were transplanted in
an advanced status of the disease (defined as acute leukemia in third
or subsequent complete remission, not in remission, or with high-
risk cytogenetics). All patients received four fractionated 12Gy total
body irradiation and chemotherapy as myeloablative conditioning.
95 patients received standard cyclosporine (CyA) and methotrexate,
and 3 patients received CyA only as a graft-versus-host disease
(GVHD) prophylaxis. Among the patients the median age was 40
years (range, 18–55 years), the median weight was 56 kg (range,
36–76 kg), the median number of cryopreserved nucleated cells
was 2.46  10 7/kg (range, 1.16–5.29  10 7/kg) and the median
number of cryopreserved CD34 positive cells was 0.93  10 5/kg
(range, 0.15–8.97 10 5/kg). 92 patients hadmyeloid reconstitution
and the median time to more than 0.5 10 9/L absolute neutrophil
count was 21 days. A higher CD34 positive cell count was indepen-
dently associated with faster neutrophil recovery (p 5 0.0001). A
self-sustained platelet count more than 50  10 9/L was achieved
in 86 patients at a median time of 42 days. Acute GVHD greater
than or equal to grade III occurred in 6 of 92 evaluable patients
and chronic GVHDoccurred in 67 of 84 evaluable patients. Among
67 chronic GVHD patients, 19 patients were extensive type. 69 pa-
tients are alive and free of disease at between 116 and 3322 days after
CBT.With a median follow-up of 1677 days, the probability of dis-
ease-free survival (DFS) at 5 years was 68.5 6 5%. The 5-year
8 Oral Presentationscumulative incidence of transplant related-mortality and relapse
was 9.96 4%, 24.86 5%, respectively. Inmultivariate analyses, ad-
vanced disease status was an adverse factor for DFS (p5 0.001) and
relapse (p5 0.007). These results suggest that adult acute leukemia
patients without suitable related or unrelated bone marrow donors
should be considered as candidates for CBT.
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THE IMPACT OF RESOLVED HEPATITIS B INFECTION ON ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMATOLOGI-
CAL MALIGNANCIES
Ramos, C.A., Saliba, R.M., Giralt, S., Khorshid, O., de Padua, L.,
Andersson, B.S., Nieto, Y.L., Popat, U.R., Qazilbash, M.H.,
Qureshi, S., Zhang, W., Champlin, R.E., de Lima, M. The University
of Texas MD Anderson Cancer Center, Houston, TX.
Serological evidence of resolved hepatitis B (HB) infection has
been associated with reactivation of hepatitis after allogeneic SCT
(alloSCT), but the true impact of this finding is unknown. We hy-
pothesized that reactivation of HB could lead to worse outcomes in
patients following alloSCT.
We conducted a retrospective matched-control analysis of the
outcomes of 77 patients with positive HB core antibody (HBcAb)
and negative HB surface antigen (HBsAg) at the time of alloSCT.
All patients had hematological malignancies (including AML,
CML, lymphoma, ALL, CLL and myeloma) and were transplanted
between 1998 and 2007. Control patients (with negative serology
for HB and other viral hepatitides) were matched by age, diagnosis,
disease risk (poor vs. good), intensity of conditioning regimen (re-
duced vs. myeloablative) and donor type. Poor risk was defined as
not being in remission or not having chemosensitive tumor before
transplant, depending on the specific disease. When possible, if
multiple matches were available, a control patient with the same ex-
act disease stage, conditioning regimen and graft source (blood or
bone marrow) was selected. Three patients were dropped from
the comparison because no appropriate matched control was avail-
able.
The control and study groups had similar baseline patient charac-
teristics regarding age (median 50 and 49, respectively), poor risk
(51% in both groups), sibling donor (73%), reduced intensity con-
ditioning (42%) and diagnosis. Follow-up serological studies done
after transplant documented reactivation of hepatitis B (defined as
the emergence of positive HBsAg) in 8 (10%) of the initially HBcAb
positive and HBsAg negative patients. Two of these patients re-
verted back to HBsAg negativity after a period of moderate eleva-
tion of liver enzymes and are long term survivors. The other 6
patients had persistent mild elevation of ALT and AST: 2 became
long term survivors, 2 died of chronic GVHD (with liver involve-
ment) and 2 died from progression of disease. Loss of antibody re-
sponse to HBc antigen with persistent negativity of HBsAg was
documented in 23 patients (30%). There were no significant differ-
ences in overall survival, relapse and non-relapse mortality and in-
cidence of acute GVHD between HBcAb positive and control
groups. In conclusion, positive HBcAb status at the time of trans-
plant does not seem to adversely affect outcomes, despite being as-
sociated with reactivation ofHB infection in at least 10% of patients
after alloSCT.
Overall survival and non-relapse mortality are comparable in HepBcAb
positive patients and matched controls after SCT
Outcome HepBcAb, % Control, % HR (95% CI) POS:
1 yr 66 64 0.99 (0.6–1.7) 0.9
2 yr 51 55 1.1 (0.7–1.8) 0.7NRM:
3 mo 11 5 2.1 (0.6–6.9) 0.2
1 yr 25 17 1.5 (0.7–3.1) 0.3
2 yr 31 21 1.5 (0.7–3.1) 0.3OS: overall survival; NRM: non-relapse mortality; HR: hazard
ratio; CI: confidence interval.16
LONG-TERM RESULTS OF A GITMO RETROSPECTIVE STUDY ON HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR PAROXYSMAL
NOCTURNAL HEMOGLOBINURIA (PNH)
Santarone, S.1, Di Bartolomeo, E.1, Bacigalupo, A.2, Tagliaferri, E.3,
Iori, A.4, Risitano, A.5, Tamiazzo, S.6, Papineschi, F.7, Rambaldi, A.8,
Spagnoli, A.9, Angelucci, E.10, Di Bartolomeo, P.1. 1BMT Center, Pes-
cara, Italy; 2BMT Center, Genova, Italy; 3BMT Center, Milano, Italy;
4BMTCenter, University La Sapienza, Roma, Italy; 5BMTCenter, Na-
poli, Italy; 6BMT Center, Alessandria, Italy; 7BMT Center, Pisa, Italy;
8BMT Center, Bergamo, Italy; 9BMT Center, S.Eugenio Hospital,
Roma, Italy; 10BMT Center, Cagliari, Italy.
Allogeneic HSCTmay cure PNH. In this study we report the re-
sults of allogeneic HSCT in 26 patients (16 males and 10 females)
affected by PNH who were transplanted between July 1988 and
May 2007. The median age at time of HSCT was 32 years (20–
60). The median time from diagnosis to HSCT was 33 months
(3–208). All patients had received various treatments before
HSCT including steroids, immunosuppressive drugs and growth
factors. Twenty-one patients were transfusion-dependent. The me-
dian number of packed red blood cells and platelet concentrates re-
ceived before HSCT was 30 (4–500) and 22 (6–86) respectively. At
time of HSCT, the median peripheral hematological counts were:
polymorphonucleates (PMN) 2200 (20–10204)  109/L, hemoglo-
bin 8.7 g/dl (4.6–11), platelets (PLT) 78 (6–355)  109/L. Two pa-
tients were severely pancytopenic at time of HSCT. Twenty-four
patients were transplanted from HLA identical siblings and 2
from matched unrelated donors. The donor’s median age was 33
years (20–59). The conditioning regimen was myeloablative for
16 patients (Busulfan and Cyclophosphamide), whereas 10 patients
received a reduced intensity conditioning including Fludarabine,
Cyclophosphamide, Melphalan and Total Body Irradiation. As
graft-versus-host disease (GvHD) prophylaxis, 11 patients received
Cyclosporine (CSA) alone and 13 were given CSA and short course
Methotrexate. Two patients received T-cell depleted marrow cells.
Twenty patients were given bone marrow cells (median nucleated
cells 4.1 (2.5–7.5)  108/kg) and 6 received peripheral blood stem
cells (median CD341 cells 4.6 (2.8–7.1)  106/Kg). Twenty-five
patients achieved primary sustained engraftment with a median
time of 17 (10–38) days to reach .0.5  109/L PMN and 27 (11–
322) days to reach .50  109/L PLT. The probability of develop-
ing grade II-IV acute GvHDand extensive chronicGvHDwas 42%
and 16% respectively. The transplant related mortality at 6 months
was 34%. Causes of death were infection in 4 patients, acute GvHD
in 1, chronicGvHD in 2, multi-organ failure in 1 and EBV lympho-
proliferative disease in 1. As of October 2007, 16 patients are alive
with complete hematological recovery and no evidence of PNH at
a median follow-up of 107 months (6–210). The 10-year Kaplan-
Meier probability of disease-free survival is 62%. No patient devel-
oped thromboembolic disease following HSCT. This study con-
firms that HSCT is a curative treatment for the majority of
patients with PNH.17
PRE-TRANSPLANT INFUSION OF NATURALLY OCCURRING DONOR
CD41 CD251 T CELLS SUPPORTS DONOR CHIMERISM IN MHC-
MATCHED ALLOGENEIC HCT
Shatry, A.M., Levy, R.B. University of MiamiMiller School of Medicine,
Miami, FL.
Resistance to MHC matched allogeneic hematopoietic stem cell
transplant (HCT) is mediated by host T cells and remains a major
complication to successful donor HCT engraftment under reduced
intensity conditioning. We examined the ability of unmanipulated
donor CD41 CD251 regulatory T cells (Tregs) to support donor
HCT engraftment to test the hypothesis that Treg suppression of
host effector CD81 T anti-donor responses would enhance donor
HCT engraftment. Mice disparate for multiple minor HA were uti-
lized for these studies: C57BL/6 (H-2b, Ly9.1-) mice conditioned
(5.5 Gy TBI) 24 hrs earlier, were transplanted with Tregs and
TCD-BM from 129P3/J (H-2b, Ly9.11) mice. By four weeks
post-HCT, the mean frequency of circulating donor-derived (total
Ly9.11) cells was significantly higher in recipients of 4  106
